Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
about
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerMolecular testing in lung cancer in the era of precision medicineTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesAcquired resistance to EGFR-targeted therapies in colorectal cancerNuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancerMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsTriptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.The quest to overcome resistance to EGFR-targeted therapies in cancer.Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancerALDH maintains the stemness of lung adenoma stem cells by suppressing the Notch/CDK2/CCNE pathway.Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer.Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung CarcinomaAntitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.Monitoring cancer stem cells: insights into clinical oncology.NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive propertiesA feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells.Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property?Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancermiR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.Lung cancer stem cells: Molecular features and therapeutic targets.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.Disruption of the expression and function of microRNAs in lung cancer as a result of epigenetic changes.
P2860
Q54881725-3373ADC2-D644-4882-BD0D-ACF46A395F95Q54881726-54AA5581-4F1E-4E17-8980-2818560DC967Q54881732-5F4F5C61-BCAE-47C2-842F-6395DD2992B9Q54881733-1EE3A347-5FCF-4699-875C-5AB46F6D8943Q54881800-4F1AD203-7DC2-4CAD-A724-6E03BFCACBCEQ54881801-38484C34-9E13-4A13-9FFB-F1D2EA0DCD85Q54881802-71D7CD96-5626-4352-B068-BF63A7B6F652Q54938470-DD9330FC-907B-4F66-8C14-338533F45B39Q54938471-4FC7437C-ACC9-4821-87E7-D38078AF1E7E
P1343
Q26749110-534CB68A-9E09-4EAA-B25D-13E0608A91CBQ26824599-C1E4855A-88E6-4C6E-962D-A0BAD389168BQ27014117-9C28C816-6337-4430-9F3B-60A71059EBD8Q27022741-81A3C06E-B612-41E3-965E-98749092583DQ27853142-C6DE76F4-70AB-4201-87B5-21EA8567968BQ28551045-FC7E9604-71CD-4D73-8197-3CE35AB8FA96Q33688875-13617D60-F867-4AB3-BCF0-64777F1C0380Q33725976-2741BF87-B2B1-4695-8CA8-52C156F9790AQ33873274-E4B36309-279D-470F-9DD5-D754DB0B902BQ33926952-C44F1A1A-AB3C-4FA8-971A-0A923D064B60Q34619336-95A90673-9E5C-4E1F-AA2C-15763D53D9B3Q35123203-2F15CAFA-3285-46D8-AF9A-78DB924EEE25Q35132170-D0F76CF7-E019-46FF-A944-CADEE1672219Q35176428-19A443D3-56D0-4C5B-924D-7BABD9DAEDD9Q35596310-0C13FDCC-D442-422A-B75F-66A265C71D89Q35602423-FD19A532-FCC1-428E-8442-07436019121DQ35833023-B2283645-1541-46F7-8F6D-BEF126AAA54BQ36095123-0793E4FC-9D01-47FE-9309-0B2531D6B390Q36198159-68623B47-5279-4753-9438-8F14B4B892B9Q36262907-2B75FB9E-B5D2-478C-8B4E-E3F3117B1BA6Q36269777-2B10D640-85D6-4CD0-9334-495C185CE43BQ36293822-A564FE56-DDA3-4058-84CD-74F537EC5CA8Q36387614-C748B455-DA90-4712-AABA-08CF4EF4C785Q36495936-A4429D07-F933-44B7-BF89-B6D090844932Q36585140-CA926ABA-ABC9-43BC-B808-8747E22D0E2DQ37173070-80FEDCD1-DBB2-4AD6-B44A-145100B87017Q37362836-5CE03A0F-4766-474D-B1FC-7DA4F92D0226Q37376411-B861C483-E9DD-4851-83C1-81F32D1F5A54Q37426768-6DBA695F-EBDE-46D5-9D58-07F5AC60F9A2Q37464844-08995F91-22DC-4DEE-A9DE-363C2735E46FQ37525231-BB490F83-6E3B-40A4-9FF0-FA079DAE1B1CQ37525819-F19F9E72-E954-4AE3-9F26-DA8FBBDD7DF8Q37529089-59958951-999A-4196-87A1-EBFE834A26E3Q37549196-C88D996D-1296-401E-A4D4-D7BAD612BE1FQ37611689-3CB65E1C-EE0E-4C89-A9CD-B6CF80A387B0Q37629583-2248829D-7CAC-4112-9DE7-FEB2BB892994Q37666880-CE738ED5-1FD4-4C38-A165-C4B5D9C53F89Q37735806-33CA6057-2CE2-4984-9B82-7A23BA78CD30Q38111684-47313D48-68B7-42D5-8EED-327572426613Q38172138-B8448E11-8E67-41A6-879E-AFF9D27F3DB3
P2860
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Acquired resistance to EGFR in ...... ke properties in cancer cells.
@en
Acquired resistance to EGFR in ...... ke properties in cancer cells.
@nl
type
label
Acquired resistance to EGFR in ...... ke properties in cancer cells.
@en
Acquired resistance to EGFR in ...... ke properties in cancer cells.
@nl
prefLabel
Acquired resistance to EGFR in ...... ke properties in cancer cells.
@en
Acquired resistance to EGFR in ...... ke properties in cancer cells.
@nl
P2093
P2860
P4510
P50
P1433
P1476
Acquired resistance to EGFR in ...... ike properties in cancer cells
@en
P2093
Adi F Gazdar
Eiki Ichihara
Hiroaki Asano
Hiromasa Yamamoto
Junichi Soh
Katsuyuki Kiura
Kelsie L Thu
Masaru Jida
Nagio Takigawa
Shinichi Toyooka
P2860
P304
P356
10.1158/0008-5472.CAN-12-4136
P407
P4510
P577
2013-03-29T00:00:00Z